Applera Confirms Share Repurchase Program for Its Applied Biosystems Common Stock
NORWALK, Conn.--(BUSINESS WIRE)--April 30, 2002--Applera Corporation (NYSE:ABI)(NYSE:CRA) today confirmed the remarks of Dennis L. Winger, Senior Vice President and Chief Financial Officer of the company, made on an investor conference call last week, that the company has been considering the repurchase of, and may repurchase, shares of Applera Corporation - Applied Biosystems Group common stock. Repurchases would be made under standing resolutions of the company's Board of Directors to replenish shares issued under the company's various stock plans. The resolutions, which have no time restrictions, delegate authority to company management to purchase shares from time to time at price levels it deems appropriate through open market or negotiated purchases consistent with the safe harbor provisions of Rule 10b-18 under the Securities Exchange Act of 1934.
About Applera Corporation
Applera Corporation comprises two operating groups. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. The Celera Genomics Group (NYSE:CRA), located in Rockville, MD and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its genomic and proteomic technology platforms to identify drug targets and diagnostic marker candidates and to discover novel therapeutic candidates. Its Celera Discovery System(TM) online platform, to be marketed exclusively through the Knowledge Business of Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. Celera Diagnostics, a joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostics tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800/762-6923. Information about Applied Biosystems is available on the World Wide Web at www.appliedbiosystems.com.
CONTACT:
Applied Biosystems
(Media)
Lori Murray, 650/638-6130
murrayla@appliedbiosystems.com
(Investors)
Linda Greub, 650/554-2349
greublm@appliedbiosystems.com
(European Media and Investors)
David Speechly, +44 207 868 1642
speechdp@eur.appliedbiosystems.com
SOURCE: Applied Biosystems |
